Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products
Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of Tscm cells that may result in better tolerability and deeper clinical responses
Cas-CLOVER has demonstrated lower off-target and translocation activity than other published technologies including CRISPR, TALENs and Base Editors
Excerpt from the Press Release:
SAN DIEGO, June 29, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced a peer-reviewed publication highlighting the potential of its proprietary Cas-CLOVER Site-specific Gene Editing System as a high-efficiency platform for the production of allogeneic CAR-T cells. The paper, titled “Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells,” was published online today in Molecular Therapy – Nucleic Acids. The paper will appear in print in the September 2022 issue of the journal.
“We are excited to publish data from this very comprehensive study of our gene editing system in T cells,” said Eric Ostertag, M.D., Ph.D., Executive Chairman of Poseida Therapeutics. “This publication validates the precision of our proprietary Cas-CLOVER system, which is utilized in the manufacture of our fully allogeneic product candidates currently in clinical trials, including P-BCMA-ALLO1 for relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for multiple solid tumor indications.”
Cas-CLOVER is a novel, high-fidelity gene editing system that can be used for high-efficiency gene editing in T cells to create allogeneic CAR-T products. In these published studies, Cas-CLOVER was used for multiplexed gene editing in resting T cells, which resulted in allogeneic product candidates with a high percentage (45%-70%) of desirable T stem cell memory (Tscm) cells.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?